SLC22A1 rs814797: Pharmacogenomics and Metformin Response
The rs814797 polymorphism is a common single nucleotide variant located within the SLC22A1 gene on chromosome 6, which encodes the organic cation transporter 1 (OCT1). Research in pharmacogenomics has explored this locus for its role in altering OCT1 activity, modulating the hepatic uptake of cationic medications such as metformin. Statistical findings associate this variant with differences in glycemic response to antidiabetic therapy, though overall clinical evidence remains limited and variable across diverse populations.
What each genotype means
Typical transporter activity
This genotype represents the most common form of the SLC22A1 gene in many populations. Research suggests that individuals with this profile typically exhibit standard hepatic uptake of metformin, though individual responses to medication can vary significantly due to other genetic and environmental factors. Please discuss your metformin dosing and glycemic control with your clinician or pharmacist.
This is the most common genotype in many global populations, though frequencies vary by ancestry.
Intermediate transporter activity
Carrying one copy of the T allele may influence the function of the OCT1 transporter protein, which is involved in the hepatic uptake of metformin. Studies on SLC22A1 variants indicate that such changes can modulate how the body processes metformin, potentially affecting glycemic response. You should consult your healthcare provider or pharmacist regarding your specific treatment plan and medication efficacy.
This heterozygous genotype is common, appearing in a significant portion of individuals across various ethnic groups.
Altered transporter activity
This genotype involves two copies of the T allele, which may be associated with reduced function of the OCT1 transporter compared to the common CC genotype. While some research links reduced-function SLC22A1 variants to differences in metformin-related glycemic response, findings remain mixed and context-dependent. Always discuss your medication response and any concerns about your diabetes management with your doctor or pharmacist.
This genotype is less common than the CC or CT profiles, with frequencies typically ranging between 0.04 and 0.16 in many European populations.
Genetic Architecture and Location of rs814797
The single nucleotide polymorphism rs814797 resides within the SLC22A1 locus, mapped to the long arm of chromosome 6 (6q25.3). This gene spans roughly 37 kilobases and comprises 11 exons that code for organic cation transporter 1 (OCT1). Human SLC22A1 is characterized by high genetic diversity, exhibiting dozens of non-synonymous, synonymous, and non-coding alterations cataloged in resources like dbSNP and Ensembl. The rs814797 variant involves a single base substitution (commonly described with C and T alleles on the genomic forward strand). Because it sits in a complex linkage region alongside other well-characterized OCT1 coding variants—such as Arg61Cys and Met420del—its functional impact is frequently evaluated in conjunction with larger transport haplotypes rather than as an isolated molecular switch.
The Biological Function of the OCT1 Transporter
The protein encoded by SLC22A1, OCT1, is a polyspecific transmembrane transport protein primarily expressed on the sinusoidal (basolateral) membrane of hepatocytes in the human liver, with secondary expression observed in the intestines and kidneys. OCT1 functions as a uniporter facilitating the cellular influx of small organic cations across the hydrophobic cell membrane down an electrochemical gradient. In human physiology, it transports endogenous cations such as thiamine and choline. In pharmacology, OCT1 is critical for the hepatic clearance and cellular distribution of cationic drugs, prominently including the frontline type 2 diabetes agent metformin, the leukemia therapeutic imatinib, and certain neuroactive compounds. Alterations in OCT1 structure or abundance can substantially change the intrahepatic concentration of these pharmacological agents.
Evidence on Drug Response and Metabolic Associations
Metformin requires OCT1-mediated uptake into hepatocytes to suppress hepatic gluconeogenesis and activate cellular AMP-activated protein kinase (AMPK). Pharmacogenomic investigations into SLC22A1 variants, including rs814797, have sought to clarify why therapeutic efficacy and gastrointestinal tolerance vary widely among patients. Some cohort studies and candidate gene screens note statistical correlations between SLC22A1 alleles and differential reductions in glycated hemoglobin (HbA1c) during metformin treatment. Additionally, genome-wide association studies cataloged at the EBI-GWAS Catalog indicate links between the SLC22A1 locus and circulating lipid levels, including low-density lipoprotein (LDL) cholesterol and blood metabolites. Nevertheless, because prospective clinical trials present mixed replication and evidence strength remains limited, current guidelines from pharmacogenomics consortia do not mandate routine genotyping for this specific locus.
Population Diversity and Allele Distribution
Data from large-scale reference databases such as gnomAD and the 1000 Genomes Project show that variants across SLC22A1 display marked ancestral divergence. The rs814797 polymorphism is common in European-descent populations, where the minor allele typically occurs at frequencies ranging between 0.20 and 0.40. In contrast, frequencies across African, South Asian, and East Asian ancestries show substantial heterogeneity. Broad genomic surveys of OCT1 function reveal that loss-of-function and reduced-function alleles are relatively widespread among individuals of European, Latino, and South Asian ancestry, but are observed at much lower rates among East Asian cohorts. These geographic differences highlight the need for cautious interpretation when extrapolating pharmacogenomic findings from one ancestral group to another.
Clinical Interpretation and Next Steps
Personal genetic test results reporting an rs814797 genotype reflect statistical correlations observed across research cohorts, not a clinical diagnosis or guarantee of drug efficacy. Inheriting one or two alternative alleles does not mean an individual cannot benefit from metformin, nor does it predict adverse effects with certainty. Drug metabolism is a multifactorial trait influenced by renal clearance pathways, lifestyle, diet, body weight, and other transporter genes such as OCT2 and MATE1. Patients should never initiate, alter, or discontinue any prescribed medication based on raw genetic data. Anyone with questions regarding how genetics might relate to their diabetes management should consult their primary physician, endocrinologist, or a clinical pharmacologist.
How common is this variant?
The rs814797 variant is a common polymorphism, demonstrating a minor allele frequency between approximately 0.20 and 0.40 in European populations, with fluctuating frequencies observed across other ancestral backgrounds.
Frequently asked questions
What does the SLC22A1 rs814797 variant do?
The rs814797 variant is a genetic polymorphism in the SLC22A1 gene, which codes for the OCT1 protein that transports cations into liver cells. Researchers study this variant to determine whether it affects the liver's uptake of medications such as metformin. However, its exact molecular impact on drug transport remains under scientific evaluation.
Does having rs814797 mean metformin will not work for me?
No, having an alternative allele at rs814797 does not imply that metformin will fail or cause side effects. Metformin efficacy depends on numerous physiological factors, organ function, and multiple transport pathways. You should never alter your prescribed medication regimen without direct guidance from your medical provider.
Is genetic testing for rs814797 recommended before starting diabetes treatment?
Routine clinical testing for rs814797 is not currently recommended by standard medical guidelines. While researchers study OCT1 variants to understand differences in drug disposition, clinical evidence is still considered limited, and management relies on routine blood sugar monitoring such as HbA1c tests.
Are other medications affected by the SLC22A1 gene?
Yes, OCT1 is a multi-specific transporter involved in the hepatic disposition of several medications beyond metformin, including certain cancer drugs like imatinib and antiviral agents. Even so, the specific influence of rs814797 on these other medications requires further clinical investigation.
Sources & further reading
Educational information only, last refreshed 9/7/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs814797?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in SLC22A1
Functional non-synonymous variant (M420del) in the organic cation transporter OCT1, significantly impacting the hepatic uptake of various drugs including metformin.
An intronic variant in the organic cation transporter gene associated with altered metformin side-effect profiles.
A variant associated with the occurrence of gastrointestinal side effects in metformin users.
Variant in SLC22A1 (OCT1) associated with altered metformin transport and glycemic response.
Also known as OCT1 p.Met420del, this loss-of-function deletion diminishes hepatic uptake and glycemic response to metformin in patients with type 2 diabetes.
A missense variant in OCT1 that impairs organic cation cellular uptake, altering clinical responsiveness and gastrointestinal tolerance to metformin.